A First-in-Human Study of CEE321 in Adult Subjects

Key inclusion Criteria for Healthy Subjects (Part A) * Written informed consent * Able to communicate well with the investigator to understand and comply with the requirements of the study, including skin biopsies * Healthy male and female subjects aged ≥18 and ≤ 65 years * Able to comply with requirement of domiciliation at the investigational site Key Exclusion Criteria for Healthy Subjects (Part A) * Subjects with a history of hypertrophic scars or keloids. * Any infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals and/or hospitalization, isolation, quarantine within 4 weeks prior to first treatment * Women of childbearing potential defined as all women physiologically capable of becoming pregnant. * History of drug or alcohol abuse within the 12 months prior to dosing Key inclusion Criteria for Atopic Dermatitis Subjects (Part B) * Written informed consent * Able to communicate well with the investigator to understand and comply with the requirements of the study, including skin biopsies * Adult male or female subjects aged ≥18 and ≤ 65 years with confirmed clinical diagnosis of atopic dermatitis (AD) Key Exclusion Criteria Atopic Dermatitis Subjects (Part B) * Subjects with a history of hypertrophic scars or keloids. * Any infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals and/or hospitalization, isolation, quarantine within 4 weeks prior to first treatment * Women of childbearing potential defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception * History of drug or alcohol abuse within the 3 months prior to dosing * Any skin disease that, in the opinion of the investigator, would confound the diagnosis or evaluation of AD disease activity * Clinical significant medical condition, including psychiatric condition, which in the Investigator's opinion may interfere with safety of subjects, study objectives or adherence to the protocol.